REQUEST SAMPLES

REQUEST A REP

SPEAKER PROGRAMS

WELL ESTABLISHED AND TOLERABLE¹

FEW PATIENTS HAD SIDE EFFECTS IN PIVOTAL TRIALS¹

	Placebo (n=984)	UBRELVY® 50 mg (n=954)	UBRELVY 100 mg (n=485)
Nausea	2%	2%	4%
Somnolence	1%	2%	3%
Dry mouth	1%	<1%	2%

Table includes adverse reactions (ARs) from ACHIEVE I and II.¹

ARs occurring in at least 2% and at a frequency greater than placebo.¹

Additional Considerations:

No medication overuse headache
has been shown with use¹

No cardiovascular warnings
or precautions¹

UBRELVY is not a controlled substance and has not been shown to be habit-forming¹

LONG-TERM SAFETY ESTABLISHED

The long-term safety of UBRELVY was further established in 813 patients in a 52-week, open-label trial, with 31,968 doses given (UBRELVY 50 mg and 100 mg). In this study, discontinuation rates due to adverse events were <3%.²

UBRELVY IS THE ONLY GEPANT WITH AN OPTIONAL SECOND DOSE.^1,3

MIGRAINE ATTACKS CAN BE UNPREDICTABLE AND NO TWO ATTACKS ARE THE SAME.⁴

Patients can take an additional dose of UBRELVY at least 2 hours after the initial dose, if needed. The maximum UBRELVY dose in a 24-hour period is 200 mg. The safety of treating more than 8 migraines in a 30-day period has not been established.¹

EXPLORE FLEXIBLE DOSING ›

Up next: See dosing

DOSING

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Drug Interactions: UBRELVY is contraindicated with concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).

Hypersensitivity Reactions: UBRELVY is contraindicated in patients with a history of serious hypersensitivity to ubrogepant or any ingredient of the product. Cases, including anaphylaxis, dyspnea, facial or throat edema, rash, urticaria, and pruritus, have been reported. Hypersensitivity reactions can occur minutes, hours, or days after administration. Most reactions were not serious, and some led to discontinuation. If a serious or severe reaction occurs, discontinue UBRELVY and institute appropriate therapy.

ADVERSE REACTIONS

The most common adverse reactions were nausea (4% vs 2% placebo) and somnolence (3% vs 1% placebo).

DRUG INTERACTIONS

Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure.
Dose modifications are recommended when using the following:
- Moderate or weak CYP3A4 inhibitors and inducers
- BCRP and/or P-gp only inhibitors

DOSAGE AND ADMINISTRATION

The recommended dose is 50 mg or 100 mg taken orally, as needed.
If needed, a second dose may be administered at least 2 hours after the initial dose.
The maximum dose in a 24-hour period is 200 mg. The safety of treating more than 8 migraines in a 30-day period has not been established.
Severe hepatic or severe renal impairment: Recommended dose is 50 mg; if needed, a second 50 mg dose may be taken at least 2 hours after the initial dose.
Avoid use in patients with end-stage renal disease.

INDICATION

UBRELVY^® (ubrogepant) is indicated for the acute treatment of migraine with or without aura in adults. UBRELVY is not indicated for the preventive treatment of migraine.

Please see full Prescribing Information.

US-UBR-230117

References: 1. UBRELVY. Package insert. AbbVie Inc; 2023. 2. Ailani J, Lipton RB, Hutchinson S, et al. Long-term safety evaluation of ubrogepant for the acute treatment of migraine: phase 3, randomized, 52-week extension trial. Headache. 2020;60(1):141-152. 3. Allergan receives U.S. FDA approval for UBRELVY for the acute treatment of migraine with or without aura in adults. Press release. Cision PR Newswire. December 23, 2019. Accessed February 29, 2024. https://www.multivu.com/players/English/8663051-allergan-ubrelvy-acute-treatment-migraine-fda-approval/ 4. Serrano D, Lipton RB, Scher Al, et al. Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. J Headache Pain. 2017;18:101.

IMPORTANT SAFETY INFORMATION

Contraindications

Drug Interactions: UBRELVY is contraindicated with concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).

IMPORTANT SAFETY INFORMATION

Contraindications

Drug Interactions: UBRELVY is contraindicated with concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).

IMPORTANT SAFETY INFORMATION

Contraindications

Drug Interactions: UBRELVY is contraindicated with concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).

IMPORTANT SAFETY INFORMATION

Contraindications

Drug Interactions: UBRELVY is contraindicated with concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Drug Interactions: UBRELVY is contraindicated with concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).

Hypersensitivity Reactions: UBRELVY is contraindicated in patients with a history of serious hypersensitivity to ubrogepant or any ingredient of the product. Cases, including anaphylaxis, dyspnea, facial or throat edema, rash, urticaria, and pruritus, have been reported. Hypersensitivity reactions can occur minutes, hours, or days after administration. Most reactions were not serious, and some led to discontinuation. If a serious or severe reaction occurs, discontinue UBRELVY and institute appropriate therapy.

ADVERSE REACTIONS

The most common adverse reactions were nausea (4% vs 2% placebo) and somnolence (3% vs 1% placebo).

DRUG INTERACTIONS

Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure.
Dose modifications are recommended when using the following:
- Moderate or weak CYP3A4 inhibitors and inducers
- BCRP and/or P-gp only inhibitors

DOSAGE AND ADMINISTRATION

The recommended dose is 50 mg or 100 mg taken orally, as needed.
If needed, a second dose may be administered at least 2 hours after the initial dose.
The maximum dose in a 24-hour period is 200 mg. The safety of treating more than 8 migraines in a 30-day period has not been established.
Severe hepatic or severe renal impairment: Recommended dose is 50 mg; if needed, a second 50 mg dose may be taken at least 2 hours after the initial dose.
Avoid use in patients with end-stage renal disease.

INDICATION

UBRELVY^® (ubrogepant) is indicated for the acute treatment of migraine with or without aura in adults. UBRELVY is not indicated for the preventive treatment of migraine.

Please see full Prescribing Information.

US-UBR-230117